1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. Anti-infection | 抗感染
  5. Antibiotic

Amoxicillin-clavulanate potassium

目录号: V53461 纯度: ≥98%
COA 产品数据 产品说明书 SDS
阿莫西林克拉维酸钾是一种抗生素。
Amoxicillin-clavulanate potassium CAS号: 74469-00-4
产品类别: Antibiotic
产品仅用于科学研究，不针对患者销售
规格 价格
500mg
1g
Other Sizes
大包装询价
020-31522723 sales@invivochem.cn
点击了解更多
  • 与全球5000+客户建立关系
  • 覆盖全球主要大学、医院、科研院所、生物/制药公司等
  • 产品被大量CNS顶刊文章引用
InvivoChem产品被CNS等顶刊论文引用
产品描述
阿莫西林克拉维酸钾是一种抗生素。阿莫西林克拉维酸钾可用于研究多种细菌感染。
生物活性&实验参考方法
参考文献
[1]. Evans J, Hannoodee M, Wittler M. Amoxicillin Clavulanate. [Updated 2021 Dec 15].
其他信息
A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.
See also: Amoxicillin; Clavulanic acid (annotation moved to).
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C24H27KN4O10S
分子量
602.66
精确质量
602.108
CAS号
74469-00-4
相关CAS号
79198-29-1 (parent)
PubChem CID
23665637
外观&性状
White to light yellow solid powder
tPSA
248
氢键供体(HBD)数目
5
氢键受体(HBA)数目
12
可旋转键数目(RBC)
6
重原子数目
40
分子复杂度/Complexity
919
定义原子立体中心数目
6
SMILES
CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C.C1C2N(C1=O)C(C(=CCO)O2)C(=O)[O-].[K+]
InChi Key
DWHGNUUWCJZQHO-ZVDZYBSKSA-M
InChi Code
InChI=1S/C16H19N3O5S.C8H9NO5.K/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);1,6-7,10H,2-3H2,(H,12,13);/q;;+1/p-1/b;4-1-;/t9-,10-,11+,14-;6-,7-;/m11./s1
化学名
potassium;(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 1.6593 mL 8.2966 mL 16.5931 mL
5 mM 0.3319 mL 1.6593 mL 3.3186 mL
10 mM 0.1659 mL 0.8297 mL 1.6593 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF
CTID: NCT05753735
Phase: Phase 2    Status: Terminated
Date: 2024-09-24
LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media
CTID: NCT05804123
Phase: N/A    Status: Completed
Date: 2024-08-22
A Trial Investigating Lu AF28996 in Healthy Adult Participants
CTID: NCT06277609
Phase: Phase 1    Status: Completed
Date: 2024-06-11
Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite
CTID: NCT02570347
Phase: Phase 4    Status: Terminated
Date: 2024-04-30
Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics
CTID: NCT06250413
Phase: N/A    Status: Not yet recruiting
Date: 2024-02-14
View More

Collaborative Urological Prosthetics Investigation Directive Research Group
CTID: NCT05100654
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-02-07

Prophylactic Antibiotic in Non-complicated Low Risk Lap Cholecystectomy (LC)
CTID: NCT06193837
Phase:    Status: Not yet recruiting
Date: 2024-01-05
Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children
CTID: NCT02848820
Phase: Phase 4    Status: Active, not recruiting
Date: 2023-10-23
Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
CTID: NCT02021006
Phase: Phase 3    Status: Active, not recruiting
Date: 2023-09-28
Effects of Antibiotic Prophylaxis on the Healing Parameters Following Surgical Crown Lengthening
CTID: NCT05925179
Phase: Phase 4    Status: Not yet recruiting
Date: 2023-07-19
Preschool Wheeze: Inflammation/Infection Guided Management
CTID: NCT02517099
Phase: Phase 2    Status: Completed
Date: 2023-03-06
EBA, Safety and Tolerability of Sanfetrinem Cilexetil
CTID: NCT05388448
Phase: Phase 2    Status: Unknown status
Date: 2022-05-24
Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps
CTID: NCT02927834
Phase: N/A    Status: Completed
Date: 2020-12-29
Preoperative Dose of Co-amoxiclav for Prevention of Postoperative Complications in Dentoalveolar Surgery
CTID: NCT03844776
Phase: N/A    Status: Unknown status
Date: 2020-10-06
The Use of Prophylactic Antibiotics in Endoscopy Sinus Surgery for Chronic Rhinosinusitis With or Without Polyp
CTID: NCT03809312
Phase: Phase 4    Status: Unknown status
Date: 2020-07-14
Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics
CTID: NCT02785549
Phase: Phase 4    Status: Completed
Date: 2020-05-14
Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
CTID: NCT02381470
Phase: Phase 2    Status: Completed
Date: 2020-03-23
The Amputation Surgical Site Infection Trial (ASSIT)
CTID: NCT02018094
Phase: Phase 4    Status: Completed
Date: 2019-07-15
Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
CTID: NCT01166945
Phase: N/A    Status: Completed
Date: 2019-06-10
Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
CTID: NCT03702894
Phase: Phase 1    Status: Completed
Date: 2019-05-14
Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia
CTID: NCT02258763
Phase: Phase 4    Status: Completed
Date: 2019-04-23
Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions
CTID: NCT03616301
Phase: Phase 1    Status: Completed
Date: 2018-10-15
Does Antibiotics Use During Surgery Help to Decrease Wound Infection and Increase Success After Ear Surgery in Children
CTID: NCT03700814
Phase: Phase 4    Status: Completed
Date: 2018-10-10
Short Duration Treatment of Non-severe Community Acquired Pneumonia
CTID: NCT01963442
Phase: Phase 2    Status: Unknown status
Date: 2017-08-14
Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
CTID: NCT01934231
Phase: Phase 3    Status: Completed
Date: 2017-07-11
C
Shorter treatment of catheter related urinary tract infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2018-03-07
The effect of rectal swab culture-guided antimicrobial prophylaxis in men undergoing prostate biopsy on infectious complications and cost of care: A randomized controlled trial in the Netherlands.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2018-02-06
INTRAVENOUS-TO-ORAL ANTIBIOTIC SWITCH THERAPY FOR SUSPECTED NEONATAL BACTERIAL INFECTIONS:
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-06-23
Antibiotic treatment alone for children with acute appendicitis; a prospective cohort study part of the Antibiotic versus Primary Appendectomy for Children with acute appendicitis; the APAC trial.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-05-18
Initial non-operative treatment strategy versus appendectomy treatment strategy for simple appendicitis in children aged 7-17 years old. APAC study
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-11-10
Multicentre controlled, randomized clinical trial to compare the efficacy and safety of ambulatory treatment of mild acute diverticulitis without antibiotics with the standard treatment with antibiotics
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-10-27
Evaluation of the efficacy of antibiotic therapy combined with corticosteroids in severe alcoholic hepatitis
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2016-07-25
ANODE: a randomised controlled trial of prophylactic ANtibiotics to investigate the prevention of infection following Operative vaginal DElivery.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-10-29
A Phase 2/3, Randomized, Open-Label, Multi-center
CTID: null
Phase: Phase 2    Status: Temporarily Halted, Completed
Date: 2014-10-10
Multiple-dose pharmacokinetics of ampicillin / sulbactam and amoxicillin / clavulanic acid during haemodialysis in longterm haemodialysis patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-07-19
Neonatal and Paediatric Pharmacokinetics of Antimicrobials study
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2013-07-19
Are phrophylactic antibiotics necessary before laparoscopic living kidney donation? A double blind, randomised, controlled trial.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-10-22
Pharmacokinetics of small spectcrum beta-lactam antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) on intensive care.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-03-09
Efficacy and Cost Efficacy of Prophylactic treatment with Antibiotics during concomitant chemoradiotherapy in patients with locally advanced head and neck cancer to prevent Aspiration Pneumonia.
CTID: null
Phase: Phase 2, Phase 3    Status: Ongoing
Date: 2011-11-15
A prospective single blind randomised controlled study to compare the outcomes of patients with diabetes and clinically non-infected ischaemic and neuropathic foot ulcers treated with and without oral antibiotics
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2011-07-13
Place de l’antibiothérapie postopératoire dans la cholécystite aiguë lithiasique. Antibiothérapie postopératoire de courte durée versus absence d’antibiothérapie postopératoire
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2009-08-19
''A prospective, randomized, open label, active comparator, multicenter, national trial to compare the efficacy and safety of sequential IV/PO moxifloxacin 400 mg once daily versus IV amoxicillin/clavulanate 2,0/0,2 g every 8 hours followed by oral amoxicillin/clavulanate 875/125 mg every 8 hours in the treatment of adult subjects with complicated skin and skin structure infections''
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2008-09-25
A national, prospective, randomized, open label study to asses the efficacy and safety of IV/PO moxifloxacin vs IV ceftriaxone + IV azithromicin followed by PO amoxicilline/clavulanate and PO claritromycin in subjects with community-acquired pneumonia
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2007-12-10
Interaction médicamenteuse entre la warfarine (Coumadine®) et l’association amoxicilline-acide clavulanique (Augmentin®)
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2007-09-14
A prospective, randomized, open-label, active-controlled study in adult subjects with acute bacterial sinusitis comparing the clinical efficacy of telithromycin (KETEK®) 800 mg once a day for 5 days versus amoxicillin-clavulanic acid (AUGMENTIN®) 875/125 mg twice a day for 10 days.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2004-11-16

相关产品
联系我们
电话: 020-31522723 QQ： 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member